Literature DB >> 1845891

Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

K M Remington1, B Chesebro, K Wehrly, N C Pedersen, T W North.   

Abstract

We selected 3'-azido-3'-deoxythymidine (AZT)-resistant mutants of feline immunodeficiency virus (FIV) in a cat cell culture system. The characterization of one of these mutants was facilitated by the development of a focal immunoassay which could accurately measure FIV infectivity. This assay was used to quantitate the susceptibility of FIV to various inhibitors. The AZT-resistant mutant was found to be cross-resistant to 3'-azido-2',3'-dideoxyuridine and 3'-azido-2',3'-dideoxyguanosine but remained sensitive to several other inhibitors (2',3'-dideoxyinosine, 2',3'-dideoxy-2',3'-didehydrothymidine, and phosphonoformate). These patterns of cross-resistance and sensitivity were similar to those of the AZT-resistant human immunodeficiency virus (HIV) that has recently been isolated from patients with AIDS (B. A. Larder and S. D. Kemp, Science 246:1155-1158, 1989). Like the AZT-resistant HIV, purified reverse transcriptase from mutant FIV failed to show resistance to the 5'-triphosphate of AZT. This mutant can be used in the FIV model system to study the mechanisms of drug resistance and to determine the pathogenicity of AZT-resistant mutants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845891      PMCID: PMC240518     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine.

Authors:  M S Smith; E L Brian; J S Pagano
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.

Authors:  B A Larder; S D Kemp; D J Purifoy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

3.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

4.  Characterization of reverse transcriptase from feline immunodeficiency virus.

Authors:  T W North; R C Cronn; K M Remington; R T Tandberg; R C Judd
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

5.  Feline leukemia virus infection as a potentiating cofactor for the primary and secondary stages of experimentally induced feline immunodeficiency virus infection.

Authors:  N C Pedersen; M Torten; B Rideout; E Sparger; T Tonachini; P A Luciw; C Ackley; N Levy; J Yamamoto
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

6.  Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.

Authors:  B A Larder; B Chesebro; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.

Authors:  J K Yamamoto; E Sparger; E W Ho; P R Andersen; T P O'Connor; C P Mandell; L Lowenstine; R Munn; N C Pedersen
Journal:  Am J Vet Res       Date:  1988-08       Impact factor: 1.156

9.  Site-specific mutagenesis of AIDS virus reverse transcriptase.

Authors:  B A Larder; D J Purifoy; K L Powell; G Darby
Journal:  Nature       Date:  1987 Jun 25-Jul 1       Impact factor: 49.962

10.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

View more
  27 in total

1.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Authors:  R A Smith; K M Remington; R M Lloyd; R F Schinazi; T W North
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 3.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Authors:  Y Q Zhu; K M Remington; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment.

Authors:  A Lundkvist; Y Cheng; K B Sjölander; B Niklasson; A Vaheri; A Plyusnin
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine.

Authors:  J Meers; G M del Fierro; R B Cope; H S Park; W K Greene; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

8.  Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.

Authors:  J M Gobert; K M Remington; Y Q Zhu; T W North
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 9.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

10.  Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Authors:  H K Medlin; Y Q Zhu; K M Remington; T R Phillips; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.